CLK1 and kidney cancer: Inhibition of CLK1 by TG003 or KH-CB19 blocks proliferation13 similar to T3 treatment, suggesting that T3 may be relevant in the treatment of diseases, such as breast and kidney cancers, where respective CLKs are deregulated.